Discovery Labs names new CEO

Discovery Laboratories has chosen W. Thomas Amick as its next CEO. Amick has been interim CEO since August 2009. Last year, the FDA rejected Discovery's application for Surfaxin as a treatment for an infant respiratory ailment, questioning the test's ability to check on the quality changes that could occur over the course of the drug's shelf life. The developer hopes to file a complete response letter in early 2011. Discovery Labs release

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”